Navigation Links
Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
Date:5/21/2008

LAWRENCEVILLE, N.J., May 21 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a marketing and distribution agreement with PharmaLink Asia Pacific Pte. Ltd. to enable Aton to expand distribution into several countries in Asia and Australia.

"This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio of products," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "PharmaLink is uniquely qualified to help us expand our reach into the Asia Pacific region."

"Aton has a portfolio of unique products, and we are excited to partner with them to serve patients who rely on the availability of these medicines," stated Dr. George Eassey, VP of PharmaLink Asia Pacific. "We look forward to a long and successful partnership with Aton."

PharmaLink is a subsidiary of the INVIDA group and a leading provider of pharmaceutical and healthcare marketing and sales services in the Asia Pacific region. PharmaLink's strong presence, with subsidiaries across Asia Pacific and associates representing 13 countries within the region, as well as the company's in-depth understanding of these markets, enables PharmaLink to enhance the potential of clients' brands and products.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

About Invida Pharmaceutical Holdings Pte. Ltd.

Invida Pharmaceutical Holdings Pte. Ltd. is a specialty pharmaceutical company and the parent of PharmaLink, which is the leading pharmaceutical and healthcare commercialization services provider in Asia Pacific; and Inovail, an independently-managed, specialty pharmaceutical company focused on market-driven innovation in the areas of dermatology, complementary oncology and female healthcare. Headquartered in Singapore, Invida's focus is in the Asia Pacific region, where it has offices in 13 countries. Its shareholders include Temasek Holdings, Quintiles Transnational and the Zuellig Group. More information about Invida can be found at http://www.invida.com.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
3. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pharmaxis Aridol Authorised for Sale in Germany
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
11. Transdel Pharmaceuticals Closes $4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the business of innovation is taking over sports. On Thursday, December 15th a ... how technology is disrupting the playing field at a Smart Talk session. Smart ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, ... The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
Breaking Biology Technology:
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):